Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1646531
PUBLISHER: GlobalData | PRODUCT CODE: 1646531
Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis
PUBLISHED:
PAGES: 162 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer's Disease market through 2033.
GlobalData estimates that the value of the Alzheimer's Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including approval of anti-ABmonoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2 million (38.8%), respectively. The smallest market is France, contributing only 1.1% to total global sales, due to the lower AD prevalent population in the country, as well as the lack of reimbursement of the current AD symptomatic therapies resulting in lower treatment rates in France.
By the end of the forecast period in 2033, GlobalData projects AD sales to rise to $19.3 billion in the 8MM, at a compound annual growth rate (CAGR) of 23.4%.
Scope
- Overview of Alzheimer's Disease, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Alzheimer's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Alzheimer's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 8MM Alzheimer's Disease therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 8MM Alzheimer's Disease therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHC306PIDR-8M
Table of Contents
Table of Contents
List of Tables
List of Figures
1 Alzheimer's Disease: Executive Summary
- 1.1 Alzheimer's market forecast to see double-digit sales growth out to 2033
- 1.2 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033
- 1.3 Opportunities to fulfil key unmet needs will remain
- 1.4 Novel late-stage pipeline drugs will be a key driver of growth
- 1.5 What Do Physicians Think?
2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
3 Disease Overview
- 3.1 Etiology
- 3.1.1 Risk genes
- 3.1.2 Deterministic genes
- 3.1.3 Protective genes
- 3.1.4 Metabolic disruption
- 3.2 Pathophysiology
- 3.2.1 Structural changes in the brain
- 3.2.2 Degenerative process
- 3.2.3 AB plaques
- 3.2.4 Neurofibrillary tangles
- 3.2.5 Neurotransmitter deficiencies
- 3.2.6 Oxidative stress
- 3.3 Biomarkers / targets of interest
- 3.4 Disease staging systems
- 3.5 Symptoms and prognosis
4 Epidemiology
- 4.1 Disease Background
- 4.2 Risk Factors and Comorbidities
- 4.3 Global and Historical Trends
- 4.4 Forecast Methodology
- 4.4.1 Sources
- 4.4.2 Forecast Assumptions and Methods
- 4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria
- 4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity
- 4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD
- 4.4.6 Forecast assumptions and methods: total prevalent cases of MCI
- 4.5 Epidemiological Forecast for AD (2023-33)
- 4.5.1 Total prevalent cases of AD by DSM-IV criteria
- 4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria
- 4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria
- 4.5.4 Total prevalent cases of AD by severity
- 4.5.5 Total prevalent cases of preclinical AD
- 4.5.6 Age-specific total prevalent cases of preclinical AD
- 4.5.7 Sex-specific total prevalent cases of preclinical AD
- 4.5.8 Total prevalent cases of MCI
- 4.5.9 Age-specific total prevalent cases of MCI
- 4.5.10 Sex-specific total prevalent cases of MCI
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the Analysis
- 4.6.4 Strengths of the Analysis
5 Disease Management
- 5.1 Diagnosis and treatment overview
- 5.2 KOL insights on disease management
6 Current Treatment Options
- 6.1 Overview
7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 More efficacious DMTs
- 7.3 Improved control of behavioral symptoms
- 7.4 Symptomatic drugs for cognition
- 7.5 Improving diagnosis earlier in the disease progression
- 7.6 Access to treatment
8 R&D Strategies
- 8.1 Overview
- 8.1.1 Targeting AB
- 8.1.2 Novel MOAs
- 8.1.3 Targeting agitation and psychosis
- 8.1.4 Targeting preclinical AD
- 8.1.5 Combination therapies
- 8.1.6 Non-pharmacological treatments
- 8.2 Clinical Trials Design
- 8.2.1 Inclusion/exclusion criteria
- 8.2.2 Endpoints
- 8.2.3 Use of biomarkers in trial design
9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive Assessment
- 10.2.1 Potential DMTs
- 10.2.2 Therapies for agitation and psychosis associated with AD
11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-Making Trends
12 Market Outlook
- 12.1 Global Markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key Events
- 12.2.3 Drivers and Barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key Events
- 12.3.3 Drivers and Barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
- 12.5 China
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers
13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 AD clinical development pipeline
- 13.4 Methodology
- 13.4.1 Forecasting methodology
- 13.5 Primary research - KOLs interviewed for this report
- 13.6 Primary research - prescriber survey
- 13.7 About the authors
- 13.7.1 Analyst
- 13.7.2 Therapy Area Director
- 13.7.3 Epidemiologist
- 13.7.4 Managing Epidemiologist
- 13.7.5 Vice President of Disease Intelligence and Epidemiology
- 13.7.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About GlobalData
- Contact Us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.